8-K: Current report filing
Published on March 24, 2000
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) March 1, 2000
----------------
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Charter)
601 Biotech Drive, Richmond, Virginia 23235
-------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (804) 648-3820
----------------
N/A
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
Effective March 1, 2000, Peter C. Einselen, submitted his resignation
as a director of the Company. Mr. Einselen served as a director since the
Company completed its initial public offering in 1997. Mr. Einselen served as a
member of the Audit, Compensation and Nominating Committees of the Company's
Board of Directors. Mr. Einselen has elected to focus his attention of the
operation of Anderson & Strudwick Incorporated, a brokerage firm by which he is
employed. The Company is actively searching for a replacement.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESSES ACQUIRED.
Not applicable.
(b) PRO FORMA FINANCIAL INFORMATION.
Not applicable.
(c) EXHIBITS.
Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC.
By: /s/ Robert B. Harris, Ph.D.
---------------------------------
Robert B. Harris, Ph.D.
President
March 24, 2000